|
WASHINGTON - With $10 million in stimulus funds in hand, Nabi Biopharmaceuticals has started a 1,000-patient Phase III trial of NicVAX (nicotine conjugate vaccine), which is the first time a vaccine to treat nicotine addiction has made it to late-stage testing.
http://www.therapeuticsdaily.com/news/ar... Rating :
 (No ratings) |
47/Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.03